TD Cowen Elevates ICON to Buy, Cites Valuation After Accounting Review Sends Shares Lower
TD Cowen moved ICON plc to a Buy rating from Hold and set a new price target of $120, down from $183, arguing the market has overreacted to an internal accounting investigation. The clinical research organization’s shares are trading at $88.62, and TD Cowen highlights a low P/E, strong free cash flow yield and a modest modeled revenue hit in coming…